Shire Continues to Deliver Excellent Growth From Cor...(come for the three months to September 3...),Health

    Interest expense
                                                              2009     2008
                                                                $M       $M

    Interest expense (US GAAP)                                 9.4     92.9
    Additional interest on settlement of appraisal rights
    litigation                                                   -    (73.0)
    Interest expense (Non GAAP)                                9.4     19.9

For the three months to September 30, 2009 the Company incurred interest expense of $9.4 million (2008: $92.9 million). Interest expense in 2008 was higher than 2009 due to accrued interest expense of $77.0 million recorded in respect of the Transkaryotic Therapies, Inc. ("TKT") appraisal rights litigation; of the $77.0 million, $73.0 million was additional interest arising from the settlement of the litigation in November 2008.

    Other income/(expense), net
                                                               2009     2008
                                                                 $M       $M

    Other income/(expense), net (US GAAP)                       7.0    (52.0)
    Other than temporary impairment of available for sale         -     54.1
    securities
    Other income, net (Non GAAP)                                7.0      2.1

Non GAAP other income, net in 2009 was higher than the same period in 2008 due to a gain recognized following the substantial modification of a property lease.

Taxation

The effective rate of tax for the three months to September 30, 2009 was 34% (2008: -103%), and the effective tax rate on Non GAAP income is 33% (2008: 19%).

The Non GAAP effective tax r
'/>"/>